COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: The first group will receive the standard treatment consisted of 200 mg Tab Hydroxychloroquine 2 times every 12 hours on the first day and then one every 12 hours up to 10 days). Inter
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years Absolute lymphocyte count <1100 / ML or SaO2 <93
Exclusion criteria
Exclusion criteria: Pregnancy or breast-feeding The physician's decision that the trial is not in the patient's interest Any circumstances that do not allow the treatment protocol to be followed easily A history of known allergies to Sofosbuvir-Velp, Trifluoprazine, Lithium and Trihexyphenidyl Drugs that their concomitant use with standard treatment or Sofosbuvir-Velpatasvir, Trifluoprazine, Lithium, and Trihexyphenidyl are contraindicated and can not be discontinued.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not need hospitalization, feels well, and is able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Not need hospitalization, feels ill but is able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Not need hospitalization, feels ill and isn't able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Need hospitalization, feels ill and isn't able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Babak Sayad
Kermanshah University of Medical Sciences
Outcome results
None listed